{
    "clinical_study": {
        "@rank": "58795", 
        "acronym": "JIA", 
        "arm_group": [
            {
                "arm_group_label": "leflunomide", 
                "arm_group_type": "Active Comparator", 
                "description": "leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily."
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized double blind clinical trial to assess efficacy of leflunomide in treatment of\n      refractory juvenile idiopathic arthritis.\n\n      Patients are randomly divided into two groups. In group 1 leflunomide and in group 2\n      placebos will be added to conventional treatment for three months. therapeutic responses\n      will be evaluated by ACRpedi (American College of Rheumatology Pediatric) scores every 4\n      weeks."
        }, 
        "brief_title": "Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Juvenile Idiopathic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Juvenile Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "30 Patients(2-19 y) are randomly divided into two groups. In group 1 leflunomide will be\n      added to conventional treatment, 5-20 mg daily based on weight.\n\n      In group 2 placebo will be prescribed as same as leflunomide. The course of treatment is 3\n      months. Every 4 weeks ACRped 30, 50, 70 should be determined to evaluate therapeutic\n      response. Side effects of treatment will be assessed by physical examination and lab tests\n      every 4 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  JIA based on ACR criteria\n\n          -  age between 2- 19 y\n\n          -  polyarticular, oligoarticular(> or = 3 active joints) or extended oligoarticular\n             subtypes\n\n          -  resistance to conventional treatment\n\n        Exclusion Criteria:\n\n          -  pregnancy\n\n          -  malignancy\n\n          -  severe active infection\n\n          -  other rheumatic diseases or overlap\n\n          -  ALT(Alanine transaminase) or bilirubin > 3 folds\n\n          -  IVIG (Intravenous immunoglobulin) treatment during last 2 weeks\n\n          -  biologic agents during last 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "19 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024334", 
            "org_study_id": "900527"
        }, 
        "intervention": {
            "arm_group_label": "leflunomide", 
            "intervention_name": "Leflunomide", 
            "intervention_type": "Drug", 
            "other_name": "arava"
        }, 
        "intervention_browse": {
            "mesh_term": "Leflunomide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "JIA", 
            "LEFLUNOMIDE", 
            "EFFICACY"
        ], 
        "lastchanged_date": "December 25, 2013", 
        "location": {
            "contact": {
                "last_name": "Zahra Rezaeiyazdi, MD", 
                "phone": "00989153115860"
            }, 
            "facility": {
                "address": {
                    "city": "Mashhad", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Khorasan Razavi"
                }
            }, 
            "investigator": {
                "last_name": "malihe bokaiyan, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis", 
        "overall_contact": {
            "email": "rezaieyazdiz@mums.ac.ir", 
            "last_name": "Zahra Rezaieyazdi, MD", 
            "phone": "009809153115860"
        }, 
        "overall_official": {
            "affiliation": "Rheumatic Diseases Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "last_name": "Zahra Rezaieyazdi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Iran: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "6 variables including: number of joints with arthritis, number of joints with limited range of motion, physician assessment, patient assessment, ESR (Erythrocyte Sedimentation Rate), CHAQ (Childhood Health Assessment Questionnaire) score.", 
            "measure": "thirty percent changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)", 
            "safety_issue": "No", 
            "time_frame": "baseline, week 4, week 8, week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024334"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mashhad University of Medical Sciences", 
            "investigator_full_name": "Zahra Rezaieyazdi", 
            "investigator_title": "Mashhad University of Medical Sciences", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "6 variables including: number of joints with arthritis, number of joints with limited range of motion, physician assessment, patient assessment, ESR, CHAQ score.", 
            "measure": "50% and 70% changes in the ACR Pediatric core set of disease activity measures in at least three of the six response variables (ACR Pedi 30)", 
            "safety_issue": "No", 
            "time_frame": "baseline, week 4, week 8, week 12"
        }, 
        "source": "Mashhad University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mashhad University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}